KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to $5.6 million.

  • CRISPR Therapeutics AG's Depreciation and Depletion rose 1666.67% to $5.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.3 million, marking a year-over-year increase of 52.08%. This contributed to the annual value of $19.4 million for FY2025, which is 104.17% up from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Depreciation and Depletion stood at $5.6 million for Q4 2025, which was up 1666.67% from $4.4 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Depreciation and Depletion registered a high of $7.3 million during Q2 2022, and its lowest value of $2.7 million during Q1 2021.
  • Moreover, its 5-year median value for Depreciation and Depletion was $4.9 million (2023), whereas its average is $5.0 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Depreciation and Depletion skyrocketed by 14800.0% in 2021 and then crashed by 3150.68% in 2023.
  • CRISPR Therapeutics AG's Depreciation and Depletion (Quarter) stood at $6.2 million in 2021, then fell by 6.45% to $5.8 million in 2022, then decreased by 15.52% to $4.9 million in 2023, then fell by 2.04% to $4.8 million in 2024, then grew by 16.67% to $5.6 million in 2025.
  • Its Depreciation and Depletion stands at $5.6 million for Q4 2025, versus $4.4 million for Q3 2025 and $4.6 million for Q2 2025.